Condition
Obesity
Locations
Denmark
Start date
12/06/2025
Identifiers
Trial ID NN9388-8175,
NCT number NCT07010432,
Eudract number Not Available
NCT number NCT07010432,
Eudract number Not Available
Summary
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide), or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo cagrilintide
DRUG: Placebo semaglutide
Study type
INTERVENTIONAL
Trial duration
Jun 12 2025 - May 03 2028
Participants
144
Phase
I
Are you eligible?
Gender
FEMALE
Age
50 to 70 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.